Hudspeth B. The burden of cardiovascular disease in patients with diabetes. Am J Manag Care. 2018;24:S268-S272.
Buse JB, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487-493.
Garber AJ, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26:107-139.
American Diabetes Association (ADA). 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetesd2021. Diabetes Care. 2021;44:S100-S110.
García-Pérez LE, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175-194.
Curtis SE, et al. Medication adherence and improved outcomes among patients with type 2 diabetes. Am J Manag Care. 2017 ;23:e208-e214.
American Diabetes Association (ADA). 5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes—2021. Diabetes Care. 2021;44: S53-S72.
Community Preventive Services Task Force. Diabetes Management: Team-Based Care for Patients with Type 2 Diabetes [Internet]. Published 2016. Accessed October 25, 202. https://www.thecommunityguide.org/findings/diabetes-management-team-based-care-patients-type-2-diabetes
Lyon C, et al. Diabetes education and glycemic control. Am Fam Physician. 2018;97:269-270.
Levengood TW; Community Preventive Services Task Force. Team-Based Care to Improve Diabetes Management: A Community Guide Meta-analysis. Am J Prev Med. 2019;57:e17-e26.
Pratley RE. The early treatment of type 2 diabetes. Am J Med. 2013;126:S2-S9.
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
Duckworth W, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776-785.
McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148-158.
Zelniker TA, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022-2031.
American Diabetes Association (ADA). 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care. 2021;44: S125-S150.
Weeda ER, et al. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis. Int J Clin Pract. 2021;75:e14060.
Toney-Butler TJ, et al. Nursing Admission Assessment and Examination. [Updated 2021 Aug 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493211/
American Diabetes Association (ADA). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44: S111-S124.
Association of Diabetes Care and Education Specialists (ADCES). ADCES diabetes education curriculum: a guide to successful self-management. 3rd ed. ADCES; 2020. Accessed November 10, 2021. https://nf01.diabeteseducator.org/eweb/DynamicPage.aspx?Action=Add&ObjectKeyFrom=1A83491A-9853-4C87-86A4-F7D95601C2E2&WebCode=ProdDetailAdd&DoNotSave=yes&ParentObject=CentralizedOrderEntry&ParentDataObject=Invoice%20Detail&ivd_formkey=69202792-63d7-4ba2-bf4e-a0da41270555&ivd_cst_key=00000000-0000-0000-0000-000000000000&ivd_cst_ship_key=00000000-0000-0000-0000-000000000000&ivd_prc_prd_key=505FF2A2-79E3-43EC-9D61-11111CCDC76D
Association of Diabetes Care and Education Specialists (ADCES). The ADCES7 Self-Care BehaviorsTM: The Framework for Optimal Self-Management. Published 2021. Accessed November 10, 2021. https://www.diabeteseducator.org/practice/practice-tools/app-resources/the-aade7-self-care-behaviors-the-framework-for-optimal-self-management?gclid=Cj0KCQjwt-6LBhDlARIsAIPRQcIYbHHaXXrWDP77a3ChnBxfS2HjyblIATbnjol9Fye5bmcOOvCGFsUaAjN_EALw_wcB
Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30:202-210.
Semaglutide [prescribing information]. Approved 2017. Revised April 2021.
Tourkmani AM, et al. The impact of telemedicine on patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia: Findings and implications. J Telemed Telecare. 2021:1357633X20985763.
American Diabetes Association (ADA). 3. prevention or delay of type 2 diabetes: standards of medical care in diabetes—2021. Diabetes Care. 2021;44: S34-S39.
Truell K. Closing care gaps in rural communities: how remote patient monitoring increases accessibility to care. Published August 24, 2021. Accessed November 10, 2021. https://www.mozzaz.com/blog/monitoring-patients-in-remote-locations

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

All of the relevant financial relationships listed for these individuals have been mitigated.

Moderator

Carol Wysham, MD

Clinical Professor of Medicine
University of Washington School of Medicine
Rockwood/MultiCare Center for Diabetes and Endocrinology
Spokane, Washington

Disclosures

Disclosure: Carol Wysham, MD, has the following relevant financial relationships:
Advisor or consultant for: Abbott; Novo Nordisk; Sanofi
Speaker or a member of a speakers bureau for: Astra Zeneca; Boehringher Ingelheim; Eli Lilly; Janssen; Novo Nordisk; Sanofi
Grants for clinical research from: Abbott; Gilead; Corcept; Novo Nordisk; Milan; Eli Lilly

Panelists

Christopher Cannon, MD

Education Director, Cardiovascular Innovation
Preventive Cardiology Section, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Disclosures

Disclosure: Christopher Cannon, MD, has the following relevant financial relationships:
Advisor or consultant for: Aegerion/Amryt; Alnylam; Amarin; Amgen; Applied Therapeutics; Ascendia; Boehringer-Ingelheim; Bristol-Myers Squibb; Eli Lilly; Janssen; Lexicon; Merck; Pfizer; Rhoshan; Sanofi
Grants for clinical research from: Amgen; Better Therapeutics; Boehringer-Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Janssen; Merck; Novo Nordisk; Pfizer
Other: Serve on Data and Safety Monitoring Boards for the Applied Therapeutics; Novo Nordisk

Jay Shubrook, DO

Professor of Medicine
Touro University California
Vallejo, California

Disclosures

Disclosure: Jay Shubrook, DO, has the following relevant financial relationships:
Advisor or consultant for: Abbott; Astras Zeneca; Bayer; NovoNordisk

Author HCP

Tory Lucas, RN, CDE

Nurse
Rockwood/MultiCare Center for Diabetes and Endocrinology
Spokane, Washington

Disclosures

Disclosure: Tory Lucas RN, CDE, has disclosed no relevant financial relationships.

Editors

Anne G. Le, PharmD

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Anne G. Le, PharmD, has disclosed no relevant financial relationships.

Gina Montanero, PharmD

Associate Medical Writer

Disclosures

Disclosure: Gina Montanero, PharmD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Best Practices in Improving Glycemic Control and Reducing CV Risk: Multispecialty Team Perspectives

Authors: Carol Wysham, MD; Christopher Cannon, MD; Jay Shubrook, DO; Tory Lucas, RN, CDE
CME / ABIM MOC / CE Released: 11/19/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/19/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for diabetologists & endocrinologists, cardiologists, primary care physicians, nurses, nurse practitioners, physician assistants, and others involved in the management of patients with type 2 diabetes (T2D) and elevated cardiovascular (CV) risk.

The goal of this activity is to improve CV risk reduction in patients with T2D.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Guideline-based strategies to improve glycemic control and reduce CV risk in patients with T2D and CV disease (CVD)
Have greater competence related to
- Using team-based management of patients with T2D and CVD
- Improving individualized and comprehensive management of patients with T2D and CVD

Disclosures

All of the relevant financial relationships listed for these individuals have been mitigated.

Moderator

Carol Wysham, MD

Clinical Professor of Medicine
University of Washington School of Medicine
Rockwood/MultiCare Center for Diabetes and Endocrinology
Spokane, Washington

Disclosures

Disclosure: Carol Wysham, MD, has the following relevant financial relationships:
Advisor or consultant for: Abbott; Novo Nordisk; Sanofi
Speaker or a member of a speakers bureau for: Astra Zeneca; Boehringher Ingelheim; Eli Lilly; Janssen; Novo Nordisk; Sanofi
Grants for clinical research from: Abbott; Gilead; Corcept; Novo Nordisk; Milan; Eli Lilly

Panelists

Christopher Cannon, MD

Education Director, Cardiovascular Innovation
Preventive Cardiology Section, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Disclosures

Disclosure: Christopher Cannon, MD, has the following relevant financial relationships:
Advisor or consultant for: Aegerion/Amryt; Alnylam; Amarin; Amgen; Applied Therapeutics; Ascendia; Boehringer-Ingelheim; Bristol-Myers Squibb; Eli Lilly; Janssen; Lexicon; Merck; Pfizer; Rhoshan; Sanofi
Grants for clinical research from: Amgen; Better Therapeutics; Boehringer-Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Janssen; Merck; Novo Nordisk; Pfizer
Other: Serve on Data and Safety Monitoring Boards for the Applied Therapeutics; Novo Nordisk

Jay Shubrook, DO

Professor of Medicine
Touro University California
Vallejo, California

Disclosures

Disclosure: Jay Shubrook, DO, has the following relevant financial relationships:
Advisor or consultant for: Abbott; Astras Zeneca; Bayer; NovoNordisk

Author HCP

Tory Lucas, RN, CDE

Nurse
Rockwood/MultiCare Center for Diabetes and Endocrinology
Spokane, Washington

Disclosures

Disclosure: Tory Lucas RN, CDE, has disclosed no relevant financial relationships.

Editors

Anne G. Le, PharmD

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Anne G. Le, PharmD, has disclosed no relevant financial relationships.

Gina Montanero, PharmD

Associate Medical Writer

Disclosures

Disclosure: Gina Montanero, PharmD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.75 contact hour(s) nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC / CE

Best Practices in Improving Glycemic Control and Reducing CV Risk: Multispecialty Team Perspectives

Authors: Carol Wysham, MD; Christopher Cannon, MD; Jay Shubrook, DO; Tory Lucas, RN, CDEFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 11/19/2021

Valid for credit through: 11/19/2022, 11:59 PM EST

processing....

Contents of This CME Activity

Clinician Handout

All sections of this activity are required for credit.

Best Practices in Improving Glycemic Control and Reducing CV Risk: Multispecialty Team Perspectives

A multidisciplinary expert panel discuss how team-based care can improve CV risk reduction in patients with type 2 diabetes.
Carol Wysham, MD; Christopher Cannon, MD; Jay Shubrook, DO

Nurses’ Role in Glycemic Management and CV Risk Reduction

Read about nurse-centric strategies for cardiovascular risk reduction in T2D management.
Tory Lucas, RN, CDE

Pre-Assessment Survey

Before you begin, please take this brief survey.

Page 1 of 5

CME / ABIM MOC / CE Information Download Slides

Activity Transcript

PDF Downloads

Clinician Handout

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Carol Wysham, MD

Panelists

Christopher Cannon, MD

Jay Shubrook, DO

Author HCP

Tory Lucas, RN, CDE

Editors

Anne G. Le, PharmD

Gina Montanero, PharmD

CME Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Best Practices in Improving Glycemic Control and Reducing CV Risk: Multispecialty Team Perspectives

Target Audience and Goal Statement

Disclosures

Moderator

Carol Wysham, MD

Panelists

Christopher Cannon, MD

Jay Shubrook, DO

Author HCP

Tory Lucas, RN, CDE

Editors

Anne G. Le, PharmD

Gina Montanero, PharmD

CME Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Best Practices in Improving Glycemic Control and Reducing CV Risk: Multispecialty Team Perspectives

Contents of This CME Activity

Clinician Handout

Best Practices in Improving Glycemic Control and Reducing CV Risk: Multispecialty Team Perspectives

Nurses’ Role in Glycemic Management and CV Risk Reduction

Pre-Assessment Survey

PDF Downloads